{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076627","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.289494+00:00","generated_at":"2026-05-15T23:45:47.281272+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront","bullets":["Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.","R&D expenses $125.9M for FY2025 vs $68.4M; net loss $113.6M vs $69.0M in 2024.","Entered collaboration with Bristol Myers Squibb for tumor-activated therapeutic; $50M upfront + up to $800M milestones.","Appointed Dr. William Go as CMO; JANX007/008/011 trials continue enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076627","json":"https://secwatch.observer/filing/0001193125-26-076627.json","markdown":"https://secwatch.observer/filing/0001193125-26-076627.md","text":"https://secwatch.observer/filing/0001193125-26-076627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526076627/0001193125-26-076627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526076627/janx-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:45:47.281272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}